Beyond Efficacy: The STAR*D Trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Psychiatrists have a range of treatments to offer patients with depression.Randomized controlled trials have demonstrated the efficacy of tricyclic antidepressants, SSRIs, cognitive behavior therapy, and interpersonal therapy.For each of these interventions, one can say with some confidence that at least 40% of a cohort with depression will show statistically significant reductions in unbiased ratings of depression.This information, while entirely commendable in the world of research, is far from satisfactory in the world of practice where an individual clinician needs to make treatment decisions to help an individual patient.The practical questions that the clinician might ask include: For this specific patient, what is the best of the available treatments?What magnitude of response can my patient realistically expect in 4 or 6 weeks?And what should I do if my patient is not sufficiently better in this period: continue or switch treatments?If the first treatment does not work, what is the next best option?So what does this approach tell us?This first report of the STAR*D trial includes only Phase 1 results (N=2,876) but already provides important, practical answers.First, only about 30% of patients met criteria for remission during citalopram treatment.For remission, the mean dose of citalopram (41.8 mg/day) was higher and the mean duration of treatment (47 days with 5.5 visits) was longer than might have been expected on the basis of current clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
The case for practical clinical trials in psychiatry.
March, J. S., Silva, S. G., Compton, S., Shapiro, M., Califf, R., & Krishnan, R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.836 · Cited by 240
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
“However, all treatments show poor efficacy in as many as half of the patients (Insel, 2006; Trivedi et al., 2006), and require multiple weeks of treatment before a substantial benefit is realized (Anderson et al.”
BackgroundThe Use of Propensity Scores to Assess the Generalizability of Results from Randomized Trials
Stuart, E. A., Cole, S. R., Bradshaw, C. P., & Leaf, P. J. (2011) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2010.00673.x · Cited by 524
Assessing the generalizability of randomized trial results to target populations
Stuart, E. A., Bradshaw, C. P., & Leaf, P. J. (2015) · Prevention Science · doi:10.1007/s11121-014-0513-z · Cited by 296
Blumberger, D. M., Mulsant, B. H., Fitzgerald, P. B., Rajji, T. K., Ravindran, A. V., Young, L. T., Levinson, A. J., & Daskalakis, Z. J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.579163 · Cited by 118
Metadata
- Authors
- Insel, T. R.
- Venue
- American Journal of Psychiatry
- Published
- 2006-01-01
- Volume
- 163
- Issue
- 1
- Pages
- 5-7
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2136887049
- Cited by
- 104
- References
- 2
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond Efficacy: The STAR*D Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.163.1.5
- The paper
- Insel, T. R. (2006). Beyond Efficacy: The STAR*D Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.163.1.5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.